Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by James Chappell and Andrea Pruijssers.
James Chappell
Connection Strength
0.618
Andrea Pruijssers
  1. Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. Cell Rep. 2020 07 21; 32(3):107940.
    View in: PubMed
    Score: 0.223
  2. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021 09 17; 373(6561):1372-1377.
    View in: PubMed
    Score: 0.060
  3. The coronavirus proofreading exoribonuclease mediates extensive viral recombination. PLoS Pathog. 2021 01; 17(1):e1009226.
    View in: PubMed
    Score: 0.058
  4. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination. N Engl J Med. 2021 01 07; 384(1):80-82.
    View in: PubMed
    Score: 0.057
  5. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020 12 17; 383(25):2427-2438.
    View in: PubMed
    Score: 0.057
  6. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020 11 12; 383(20):1920-1931.
    View in: PubMed
    Score: 0.056
  7. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci Transl Med. 2020 04 29; 12(541).
    View in: PubMed
    Score: 0.055
  8. Small-Molecule Antiviral ß-d-N4-Hydroxycytidine Inhibits a Proofreading-Intact Coronavirus with a High Genetic Barrier to Resistance. J Virol. 2019 12 15; 93(24).
    View in: PubMed
    Score: 0.053
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.